HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 303 filers reported holding HAEMONETICS CORP in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,111,563 | +6.4% | 157,530 | +1.1% | 0.08% | +13.3% |
| Q2 2023 | $13,266,493 | +3.5% | 155,820 | +0.6% | 0.08% | +1.4% |
| Q1 2023 | $12,812,750 | +4.9% | 154,836 | -0.3% | 0.07% | +2.8% |
| Q4 2022 | $12,217,569 | +2.0% | 155,341 | -4.0% | 0.07% | -5.3% |
| Q3 2022 | $11,983,000 | +12.9% | 161,870 | -0.6% | 0.08% | +16.9% |
| Q2 2022 | $10,616,000 | -82.7% | 162,861 | -83.2% | 0.06% | -79.9% |
| Q1 2022 | $61,388,000 | +26.2% | 971,011 | +5.8% | 0.32% | +32.2% |
| Q4 2021 | $48,657,000 | -32.3% | 917,358 | -9.8% | 0.24% | -38.0% |
| Q3 2021 | $71,819,000 | +2.3% | 1,017,413 | -3.4% | 0.40% | +5.6% |
| Q2 2021 | $70,171,000 | -40.2% | 1,052,983 | -0.4% | 0.37% | -44.5% |
| Q1 2021 | $117,420,000 | +5.2% | 1,057,738 | +12.5% | 0.67% | -3.4% |
| Q4 2020 | $111,650,000 | – | 940,216 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |